mosaic quadrivalent influenza vaccine (FluMos-v1) / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults (clinicaltrials.gov) - P1 | N=63 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=35 ➔ 63

Enrollment change • Infectious Disease • Influenza • Respiratory Diseases

Mosaic quadrivalent influenza vaccine single nanoparticle characterization. (PubMed, Sci Rep) - P1 | "Additionally, we have determined percentages of multivalent (mosaic) nanoparticles with four, three, or two HA proteins. The integrated imaging and physicochemical methods we have developed for single nanoparticle multivalency will serve to further understand immunogenicity data from our current FluMos-v1 clinical trial."

Journal • Infectious Disease • Influenza • Respiratory Diseases

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults (clinicaltrials.gov) - P1 | N=35 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Influenza • Respiratory Diseases

Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA. (PubMed, Vaccine) - "The dissociated HATs were then quantified against their corresponding HAT standard solutions for three development lots of FluMos-v1 vaccine and the assembly ratio of all four HATs was calculated. The molar ratio of different HATs incorporated into this quadrivalent NP vaccine was consistent and determined as H3:H1: HBV: HBY ∼ 1.00:0.92:0.96:0.87, which was close the expected 1:1:1:1 ratio and confirmed a proper assembling of multivalent NP."

Journal • Infectious Disease • Influenza • Respiratory Diseases

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults (clinicaltrials.gov) - P1 | N=35 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting | Trial completion date: May 2023 ➔ Jan 2024 | Trial primary completion date: May 2023 ➔ Jan 2024

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Development and validation of a mass spectrometry based analytical method to quantify the ratios in hemagglutinin trimers in quadrivalent influenza nanoparticle vaccine - FluMos-v1. (PubMed, Anal Methods) - "A quadrivalent influenza nanoparticle vaccine (FluMos-v1) offers long-lasting protection against multiple influenza virus strains and is composed of four strains of hemagglutinin trimer (HAT) assembled around a pentamer core. Here we report an LC-MS/MS analytical development and validation method to measure the percentage of each HAT component in FluMos-v1."

Journal • Infectious Disease • Influenza • Respiratory Diseases